HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab


Dear Editor, Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as standard therapy for aggressive adult T cell leukemia/lymphoma (ATLL) patients to achieve a long-term survival [1, 2]. AntiCCR4 monoclonal antibody mogamulizumab (Mog) is the first immunotherapeutic agent targeting ATLL. Since CCR4 is expressed on regulatory T… (More)
DOI: 10.1007/s00277-016-2856-y


1 Figure or Table

Slides referencing similar topics